Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Adult subjects with malignant disease appropriate for treatment with carboplatin/paclitaxel,
carboplatin/etoposide, topotecan, docetaxel or erlotinib according to the standard dosing
regimen will be enrolled in each treatment arm.
Primary objective: Determine the MTD.
Secondary objectives: Response rates, PK, quantify MP-470 on PK of SOC, and collect
pharmacodynamic information. Evaluate the overall safety of MP-470 when co-administered with
specific SOC treatments.